In a market dominated by Robinhood investors, it seems everyone wants to uplist to the Nasdaq to capture a portion of the wild trading experienced as of late. Mydecine Innovations (CSE: MYCO) is the latest such firm looking to enter that realm, with the announcement this morning that the company has filed an application to uplist to the Nasdaq.
The listing, as is commonly stated, is intended to, “open the investment opportunity to a large and more diverse pool of investors and help create greater shareholder value.” The company also refers to the boilerplate “accelerate growth phase” terminology when describing itself and why it needs to uplist to the big board.
In connection with the application to uplist, the company expects to file a Form 20-F Registration Statement with the US Securities and Exchange Commission in due course.
It’s unclear if the company intends to remain on the CSE following the uplisting, with the firm instead stating that it will continue to trade on the CSE under its current symbol during the review process.
Mydecine Innovations last traded at $0.51 on the CSE.
Information for this briefing was found via Sedar, and Mydecine Innovations Group. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
